DSM Pharmaceutical Products has just opened its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane.
Built in partnership with BioPharmaceuticals Australia (BPA) and with cooperation from the government of Queensland and the Commonwealth of Australia, the new facility offers cGMP mammalian cell culture contract manufacturing services ranging from process development to commercial manufacturing.
The Brisbane facility reportedly has an output capability of 500 kg and has expansion space available for further capacity utilization.
“With its flexible design and use of single-use technology, the facility represents the model for the future of biomanufacturing,” Lukas Utiger, president and CEO of DSM Pharmaceutical Products, said in a statement. “It represents an important milestone in the development of Australia-based mammalian cell-based manufacturing of biopharmaceuticals and extends DSM’s contribution to the global biotechnology market.”